Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas is a PHASE1 clinical asset sponsored by Silenseed Ltd in Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer. SEO and diligence focus: siG12D LODER, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Pancreatic Ductal Adenocarcinoma
Modality: small molecule
Target: siG12D LODER
Sponsor: Silenseed Ltd
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: siG12D LODER
View original source fields
Condition raw: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Condition normalized: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: siG12D LODER
Target normalized: siG12D LODER